Neoantigen vaccines are an early, pre-commercial market: there is no approved personalized neoantigen vaccine anywhere in the world, so every “market size” figure is an analyst's extrapolation off a tiny base. The investable story is less a market than a small set of binary clinical readouts — above all Moderna and Merck's Phase 3 program, which most of the sector's value is riding on.
The narrow neoantigen-vaccine market is tiny and pre-revenue — analyst forecasts cluster near $0.45B today growing ~15% a year, but their wide spread is the tell that these are models, not observed sales.
Definitions matter here, and they get conflated constantly. The narrow neoantigen-vaccine segment — mutation-specific, per-patient shots — is small today. The broader personalized cancer vaccine category folds in older dendritic-cell and tumor-lysate approaches, and the cancer vaccine market overall is dominated by prophylactic shots like HPV, which is why that headline number is so much larger and a poor proxy for the personalized opportunity.
| Market definition | 2025 est. | Projected | CAGR |
|---|---|---|---|
| Neoantigen vaccine (narrow) | ~$0.4–0.5B | ~$1.3–1.8B by 2032–34 | ~15% |
| Personalized cancer vaccine (broad) | ~$0.2–0.4B | wide range | ~6–45% |
| Cancer vaccine (all, incl. HPV) | ~$11–13B | ~$29–33B by 2034 | ~11% |
The ~$12B headline is mostly prophylactic HPV shots — a poor proxy for the personalized opportunity, which is ~25× smaller.
The honest read: the narrow neoantigen reports cluster around ~$0.45B today growing ~15% a year, but that apparent agreement is partly an artifact of firms citing one another. What actually moves valuations is whether the lead programs convert their mid-stage signals into pivotal wins — and a single Phase 3 miss would reprice the whole space.
Shaded band ≈ 12.5–16.6% CAGR — the spread across published forecasts. Pre-commercial: every figure is an extrapolation off a near-zero base.
Two well-funded mRNA leaders and a handful of mid-size and AI-driven challengers share one mechanism — sequence the tumor, predict neoantigens, pair the vaccine with a checkpoint inhibitor — so execution and indication choice are what separate them.
The field has consolidated into two well-funded mRNA leaders, a handful of mid-size and AI-driven challengers, and a growing list of cautionary tales. The mechanism — sequence the tumor, predict the best neoantigens, build a per-patient vaccine, pair it with a checkpoint inhibitor — is shared; execution and indication choice are what separate them.
| Company | Lead program | Stage & signal |
|---|---|---|
| Moderna + Merck | intismeran autogene (mRNA-4157 / V940) | Phase 3 (melanoma INTerpath-001, fully enrolled; NSCLC). With Keytruda, cut recurrence-or-death risk ~49% vs. Keytruda alone; benefit held at the 5-year update (Jan 2026). |
| BioNTech + Genentech / Roche | autogene cevumeran (BNT122) | Phase 2. Striking pancreatic Phase 1 durability — but the same platform missed in melanoma and crossed a futility boundary in colorectal, a sobering counterweight. |
| Transgene + NEC | TG4050 (myvac viral vector + NEC AI) | Phase 1/2. Durable disease-free survival and T-cell responses at 24 months in resected head & neck cancer. |
| Evaxion | EVX-01 (AI-Immunology platform) | Phase 2 with Merck's Keytruda in melanoma; AI predictions correlated with observed immune responses. |
| Nouscom | NOUS-209 (off-the-shelf shared neoantigens) | Phase 1b/2 in MSI tumors and Lynch-syndrome interception; oversubscribed ~€76M Series C. |
Stages as of mid-2026; all programs remain investigational. Moderna/Merck sit a full phase ahead of the field.
Durable private value is concentrating less in standalone vaccine developers and more in the AI and diagnostics infrastructure — sequencing, neoantigen prediction, and MRD monitoring — that every vaccine program needs.
A telling pattern: the durable private value is concentrating less in capital-intensive standalone vaccine developers and more in the AI and diagnostics infrastructure around them — the sequencing, neoantigen prediction, and minimal-residual-disease (MRD) monitoring that every vaccine program needs.
- Personalis — NeXT and NeXT Personal, ultra-sensitive tumor-informed MRD; commercialization tie-up with Tempus extended to 2029.
- Tempus AI — multimodal oncology AI; immunogenomics, neoantigen load, and an AI Immune Profile Score.
- Caris Life Sciences — MI Cancer Seek won FDA approval (Nov 2024); IPO'd in 2025.
- NEC OncoImmunity — the AI neoantigen-prediction engine behind Transgene's TG4050.
- BostonGene · Elicio — omnimodal IO biomarkers; and shared-KRAS off-the-shelf neoantigen shots.
The graveyard is equally instructive. Genocea wound down in 2022. Gritstone bio — which had a respected AI neoantigen platform — filed Chapter 11 in October 2024 after a Phase 2 colorectal miss, its assets later sold for about $21M. Achilles Therapeutics discontinued its clonal-neoantigen cell therapy and wound down through 2024–25, selling core technology to AstraZeneca for $12M. The lesson investors draw: a scientifically credible platform can still run out of money before it is validated.
The space is bifurcating into a “show me the Phase 3” story — one durable melanoma readout carries the bull case while two recent BioNTech/Gritstone failures anchor the bear case.
The space is bifurcating. One program is carrying most of the bull narrative; two recent failures anchor the bear case. Increasingly this is treated as a “show me the Phase 3” story rather than a settled thesis — which is as much a regulatory question as a clinical one, since approving a medicine that is different for every patient is its own hurdle. For how the FDA actually handles that, see how the FDA regulates an N-of-1 cancer vaccine.
- mRNA manufacturing was de-risked at scale during COVID — a new per-patient sequence can be made in weeks, not months.
- Moderna/Merck's melanoma benefit is durable at five years and biologically rational, paired with an established checkpoint inhibitor.
- A large oncology addressable market and a clear multi-indication expansion path (melanoma, lung, bladder, kidney, head & neck).
- Bespoke, per-patient manufacturing is costly and logistically hard; reimbursement for an N-of-1 biologic is unproven.
- The thesis leans heavily on one pivotal melanoma readout — long, expensive, and binary.
- The same mechanism has already failed twice for BioNTech in melanoma and bankrupted Gritstone in colorectal. This is not a de-risked category.
On the AI angle specifically, investors are sober: neoantigen prediction is necessary but, on its own, trending toward a commodity. Only a small fraction of predicted neoantigens are truly immunogenic — one benchmark validated roughly 6% — so “we have a better predictor” claims get discounted. The investable AI angle is more picks-and-shovels (sequencing, MRD) than “the algorithm picks the winner.”
A handful of pivotal readouts will de-risk the category or not — above all the fully-enrolled INTerpath-001 melanoma Phase 3, the single biggest event for the entire theme.
- INTerpath-001 (melanoma, Phase 3) — Moderna/Merck, ~1,089 patients, fully enrolled; a potential 2026 readout. The single biggest event for the entire theme.
- INTerpath NSCLC (Phase 3) — extends the platform beyond melanoma; reads out later.
- Autogene cevumeran in pancreatic — BioNTech/Genentech's surviving high-interest indication; early but unusually durable Phase 1 follow-up.
- BioNTech adjuvant colorectal — a near-term tie-breaker on whether that platform works anywhere after the melanoma misses.
A single Phase 3 miss would reprice the whole space — this is a “show me the readout” story, not a settled thesis.
The bottom line for a sober reader: this is, for now, a single-asset story wearing a platform's clothing. The lead melanoma data is genuinely encouraging — but the category will be de-risked, or not, by a handful of pivotal readouts over the next year or two. The daily brief tracks each one as it lands.